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Inappropriate opinion on normal blood pressure and
impact on compliance in chronic hemodialysis
Abstract
Background: Arterial hypertension (AH) associated with cardiovascu-
lar disease is often responsible for morbidity and mortality in chronic hemo-
dialysed patients (CHD). Noncompliance with antihypertensives could be
related to distorted view on normal blood pressure (NBP).
Purpose: To examine if CHD patients consider increased blood pressure
(BP) for normal and consequently have poor compliance with antihyper-
tensive therapy.
Patients and Methods: 202 CHD patients (aged 25–85 years) at Uni-
versity Hospital Centre Osijek, Croatia, completed a questionnaire on max-
imal NBP, compliance to antihypertensives and symptoms related to BP
variations. Data on medical history and AH control were obtained from
their medical records. Optimal BP before hemodialysis (HD) session was
considered <140/90 mmHg, mean arterial pressure (MAP) <107 mmHg,
corresponding to the high normal BP according to guidelines ESH-ESC
2007.
Result: 57% of 202 patients declared maximum acceptable systolic BP
>139 mmHg (median 150, range 140–180). Majority of them would not
take antihypertensives and reported symptoms accurring by BP lower than
preferred. The year of AH diagnosis differed significantly from the initial
year of antihypertensive therapy (P<0.001), indicating delayed treatment.
Patients with distorted view on NBP were older (P=0.012), took more
antihypertensives (P=0.043) and had higher predialysis MAP (P=0.019)
in comparison with other patients.
Conclusion: CHD patients consider NBP to be higher than officially
recommended. Majority had poorly regulated AH due to noncompliance
with antihypertensives therapy. Different view on NBP could be attributed
to their symptoms occurring by BP lower than preferred. They seem to be
adapted to increased BP. The question remains whether this is a consequence
of delayed AH treatment or inadequate guidelines for CHD patients.
INTRODUCTION
Arterial hypertension (AH) is common among chronic hemodia-lysed patients. Hypertension is observed in approximately 80% to
90% of patients by the time chronic kidney disease (CKD) progresses to
end-stage renal failure (1). Cardiovascular diseases (CVD) remain the
leading cause of death among patients on dialysis and after renal trans-
plantation (2). According to Collins et al., 45% of all deaths of hemo-
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there are no specific guidelines for this population of pa-
tients. According to the current literature and guidelines
(National Kidney Foundation Task Forces on Cardio-
vascular Disease), blood pressure (BP) is recommended
to be lower than 140/90 mmHg in hypertensive patients
on renal replacement therapy (4). The prevalence of AH
in general population is higher than it was several de-
cades ago, and in Europe it is approximately 40%. Ac-
cording to the results of the epidemiology of AH in
Croatia study (EH-UH), the prevalence of AH in Croa-
tia is 37.5% (5). Women are more aware of the disorder,
they were treated more often, and BP control was more
frequently achieved than in men. The prevalence of CKD
in stage 3–5 (glomerular filtration rate <60 mL/min/
L.73 m2) in general population was 4.7%, but consider-
ing also those suffering from hypertension, diabetes and
those older than 55 years the prevalence of CKD could be
up to 93.2% (6). The most common pattern of BP in dial-
ysis patients is systolic hypertension associated with a
wide pulse pressure due to atherosclerotic arterial stiff-
ness (7, 8). Insufficient volume removal is often the ma-
jor factor responsible for dialysis-refractory hypertension
(9, 10). Both fluid overload and dehydration are linked to
an increased morbidity in hemodialysed patients (11).
Volume depletion during hemodialysis (HD) session can
cause intradialytic hypotension. It is associated with ap-
pearance of symptoms, which makes treatment unpleas-
ant and indirectly affects the prescribed treatment and
patients' adherence to taking antihypertensive treatment
before HD session (12). Several additional factors also
contribute to increase in sympathetic outflow in this pop-
ulation including renal ischemia, increased activity of
the renin–angiotensin system, nocturnal hypoxemia and
prevalent co-morbidities such as chronic heart failure
(13, 14, 15). Renal ischemia is probably an important pri-
mary event leading to increased sympathetic nervous
system activity. Enhanced sympathetic nervous system
activity appears to be a direct effect of primary NO defi-
ciency and plays an important role in the genesis of hy-
pertension in NO deficiency. NO synthetase activity pro-
gressively decreases in chronic renal failure, which re-
sults in unbalanced NO and angiotensin activity. Chro-
nic NO deficiency induced intraglomerular platelet ag-
gregation and glomerular injury, which was ameliorated
by renal denervation. Progression of renal insufficiency
could be reduced by using a1-adrenoceptor blocker or
the ACE inhibitor. Observational studies in HD patients
have yielded paradoxical results on the relationship be-
tween BP level and cardiovascular morbidity and mortal-
ity risk. These relationships may be different from those
observed in general population (16). Although increased
BP is associated with adverse outcomes in general popu-
lation, elevated BP is associated with decreased mortality
in patients with end-stage renal disease undergoing main-
tenance HD (17). Low BP appears to be associated with
higher mortality during the early years of dialysis, whe-
reas high BP is associated with mortality in long term fol-
low-up. Increased mortality risk associated with lower
BP indicates the presence of heart failure and inability to
increase BP level (18).
Arterial hypertension is more common in both type 1
and type 2 diabetes mellitus than in general population
(19). Kidney disease is almost always the source of hyper-
tension in type 1 diabetes. In type 2 diabetes, many peo-
ple who have hypertension, impaired glucose tolerance
and other features of metabolic syndrome will eventually
develop diabetes mellitus. Hypervolemia in diabetes can
be partially explained by active reabsorption of glucose
and ketones in the kidney as sodium salts, abnormalities
in several sodium- and volume-regulating systems, such
as the renin-angiotensin-aldosteron system, insulin, at-
rial natriuretic peptide, sodium transport pathways, in-
trarenal dopamine production, vessel compliance, and
renal function, resulting in an enhanced propensity to
hypertension (20). It is recommended that diabetic pa-
tients should be treated with antihypertensives if BP is
130/80 mmHg (21). People with type 2 diabetes have a
greater incidence of cardiovascular disease, cerebrovas-
cular disease and renal disease than the general popula-
tion. Each 10 mmHg reduction in systolic BP was associ-
ated with a 12% decrease in the risk of any end point
related to diabetes and a 15% reduction in the risk of
death related to diabetes (22). In the Atherosclerosis Risk
in Communities (ARIC) study, individuals with systolic
BP (SBP)/diastolic BP (DBP) >140/90 mmHg were 2.5
times more likely to develop diabetes than their normo-
tensive counterparts (23, 41).
Observational studies and their meta-analysis have
shown that late referral of patients with CKD to ne-
phrologists is associated with poor clinical outcomes (21,
24). The National Kidney Foundation-Kidney Disease
Outcomes Quality Initiatives (K-DOQI) guidelines rec-
ommend the patients with CKD to be referred to neph-
rologists when glomerular filtration rate (GFR) falls be-
low 30 mL/min (Stage 4 CKD), and earlier if possible
(25). Despite the existence of these guidelines, nearly
15–80% of patients who start dialysis are referred late
(26). Noncompliant behavior is likely one of the most
common causes of treatment failure for chronic condi-
tions (27). Lack of symptoms in hypertension together
with a low tolerability of some antihypertensive drugs are
some of the most common reasons for patients to discon-
tinue treatment or not take the medication as prescribed.
We have frequently encountered chronic HD patients
avoiding prescribed antihypertensive medication. We ex-
amined the hypothesis that chronic HD patients hold in-
creased BP values for normal and that their poor BP con-
trol is partly related to consecutive noncompliance with
antihypertensive medication.
PATIENTS AND METHODS
The study included all 202 chronic hemodialysed pa-
tients (University Hospital Centre Osijek, Osijek, Croa-
tia), ranging in age from 25 to 85 years (mean 64 ± 13
years, 103 males). The study was conducted in 2010. All
patients provided informed consent for participation in
the study. 24 patients were undergoing HD two times
and 178 patients three times per week, using dialyzers
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with bicarbonate buffer and polysulfone membranes.
The study was conducted using a questionnaire and by
taking data from medical records. Current arterial BP
control data were updated from their HD records. The
questionnaire was completed during a regular dialysis
session. The questionnaire consisted of several types of
questions: some referred to the patients' general charac-
teristics (age, gender, education); other questions were
related to the patients' opinion on which factors could
have influenced BP variations, e.g. smoking, fat food,
salt, obesity and physical activity. Other questions were
related to their compliance to the treatment regimen: if
they were taking antihypertensives regularly, before HD
session, depending on BP variations, which antihyper-
tensives were currently prescribed, about their knowl-
edge about medicines for AH. Several questions were re-
lated to the patient’s history of the disease: duration of
AH, treatment of AH and dialysis duration. Table 1 and
Table 2 show the questions addressed to patients. BP was
measured with mercury column sphygmomanometer on
the opposite arm of vascular access in a recumbent sub-
ject before, during and after HD session by a nurse as
regular procedure in monitoring patients during a HD
session. Disappearance of bruits (Korotkoff phase V)
identified diastolic BP. Means of the BP values during
three consecutive hemodialysis sessions were taken from
their recent medical records. Mean arterial pressure
(MAP) was measured according to the formula: MAP =
(systolic BP + 2 ´ diastolic BP)/3. Categories of BP val-
ues were compared to those recommended by the guide-
lines (National Kidney Foundation Task Forces on Cardio-
vascular Disease ESH-ESC 2007). We also took the data
on diabetes, antihypertensive medication and underly-
ing renal disease from medical records. Regarding the
patients’ perception of BP values, we divided the subjects
into the two groups: the patients who considered maxi-
mum normal systolic BP lower than 140 mmHg (Sub-
group 1) and the patients who considered maximum
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TABLE 1





Declared maximum normal systolic
BP <140 mmHg (n=61, 30.2%)
Subgroup 2
Declared maximum normal systolic




Gender males:females 103:99 36 : 25 58 : 58
1Statistical significance in age (years) between the subgroups; t=–2.546 P=0.012. There is no statistical difference in other patients’ charac-
teristics.
TABLE 2
Answers to questions on arterial hypertension.
Question





<140 mmHg (n, %)2
Declared maximum
normal systolic BP
140 mmHg (n, %)2
Taking antihypertensive treatment regularly (n, %) 123 (71.9%) 31 (63.3%) 81 (75%)
Currently prescribed antihypertensive (n, %) 132 (77.2%) 35 (70%) 87 (80.5%)
Knowledge about medicines for AH (n, %) 34 (16.8%) 7 (11.5%) 24 (20.7%)
Taking antihypertensive treatment before hemodialysis session (n, %) 107 (63.3%) 30 (60%) 68 (65.4%)
Taking antihypertensives depending on BP variations (n, %) 111 (64.9%) 32 (61.5%) 69 (65.1%)
Impact of obesity on BP values (n, %) 122 (75.3%) 42 (76.4%) 72 (76.6%)
Impact of salt on BP values (n, %) 164 (89.6%) 52 (85.3%) 99 (91.7%)
Impact of fat food on BP values (n, %) 147 (82.1%) 51 (86.4%) 85 (80.2%)
Impact of smoking on BP values (n, %) 122 (74.4%) 46 (82.1%) 70 (72.9%)
Impact of physical activity on BP values (n, %) 128 (73.6%) 47 (82.5%) 72 (69.9%)
Having enough physical activity (n, %) 80 (42.1%) 20 (33.3%) 54 (47.4%)
Having sufficient money for medicines (n, %) 104 (54.7%) 35 (58.3%) 60 (52.2%)
1Percentages do not always match the total number of patient because of the missing answers.
2There is no statistical difference between the subgroups.
normal systolic BP higher than 140 mmHg (Subgroup
2). The patients gave information if they had experi-
enced symptoms at lower BP levels than those preferred.
Symptoms were categorized as weakness, dizziness, nau-
sea, headache, sweating, heat and visual disturbances.
Nevertheless, majority of the patients would not take
medicine as prescribed if they were asymptomatic for in-
creased BP at the time.
All the data were analyzed using statistical package
for social sciences (SPSS) version 17 (SPSS inc, Chicago,
IL, SAD). Normal distribution of continuous variables
was considered if skewness was <1. Mean values of con-
tinuous variables were categorized as mean ± standard
deviation for normal distribution of variables, but if vari-
ables were not normally distributed, or a sample size was
too small, then the median and range were used. Nomi-
nal variables were shown as frequencies and percentages.
Independent-sample T-test was used to compare the
means of between among two groups of patients for nor-
mally distributed data. The Mann-Whitney test was used
as test for assessing the difference between two inde-
pendent . Chi-square test was used to determine differ-
ences among two independent samples for normal data.
The differences were considered significant when P-va-
lue was <0.05. Because of the missing answers, the per-
centages do not always match the total number of the pa-
tients. 17 patients died during the implementation of the
study. Other patients could not provide answer due to
their poor mental or physical status. They were also in-
cluded in the analysis, when possible. Thus, we consid-
ered some unanswered questions as missing, rather than
dropped out cases, while the study was of cross-sectional
type.
RESULTS
202 chronic HD patients were included in the study.
Regarding the patients' perception of BP values, we di-
vided the subjects into the two groups: patients who con-
sidered maximum normal systolic BP to be up to 140
mmHg (Subgroup 1) and patients who considered maxi-
mum normal systolic BP to be higher than 140 mmHg
(Subgroup 2). Mean age was 64±13 years, age range from
25 to 85 yrs. Patients that didn't have appropriate view on
normal BP were older (65±12 years) in comparison with
those with correct BP perception (60±13 years); (t=
–2.546, P=0.012). There was no statistical difference in
other patients' characteristics between the stated sub-
groups. No difference in the opinion on normal arterial
blood pressure value was found between 91 patients co-
ming from rural (45%) and 111 patients from urban
(55%) area, either. Underlying renal disease was chronic
glomerulonephritis in 56 subjects, chronic interstitial ne-
phritis in 49 subjects, autosomal dominant polycystic
kidney disease in 12 subjects, diabetes mellitus in 40 sub-
jects, AH in 27 subjects and other underlying renal dis-
ease in 5 subjects, while an unknown underlying renal
disease was recorded in 13 subjects. The differences be-
tween the two subgroups are shown in Table 1. Median
duration of HD for all participants was 4 years, range
0–26; mean duration of AH was 15±11 years; median of
the treatment of AH was 10 years, range 0–26. All pa-
tients were considered to suffer from AH, for they were
prescribed antihypertensives at least for some time dur-
ing their illness.
All 202 patients were interviewed, but due to the poor
mental or physical condition as many as 25 of 202 pa-
tients (12.4%) were not able to decide upon their view on
the normal BP values. Those 25 patients did not differ
from the others that declared the opinion on normal arte-
rial blood pressure values in age and gender distribution
and the duration of arterial hypertension, but were un-
dergoing chronic HD for a significantly shorter period of
time (0.5 years, min. 0, max. 7 vs median 4 years, min. 0,
max. 26; Z=–4.571, P<0.001, Mann-Whitney test). Pa-
tients with different perspective on BP values had similar
opinion on the factors affecting BP values. Table 3 shows
the number of patients who declared maximum normal
systolic BP, current number of antihypertensive drugs,
mean systolic BP recent value and data on delayed AH
treatment (1 year after AH diagnosis). 30.2% of patients
in the Subgroup 1 declared maximum acceptable BP
median to be 130 mmHg (100–135) and 57.4% of the pa-
tients in Subgroup 2 declared maximum acceptable sys-
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TABLE 3
Declared maximum normal systolic blood pressure, current number of antihypertensive drugs, mean systolic blood pres-
sure and delayed arterial hypertension treatment between the two subgroups divided according to the declared maximum

























1Z=–11.227, P<0,001; Mann-Whitney test
2t= –2.463, P=0.015;
3Z=–2.025, P=0.043; Mann-Whitney test
4Z=–2.088 P=0.037; Mann-Whitney test
tolic BP to be higher than 139 mmHg (median 150
mmHg, 140–180); z=–11.227, p<0.001, (Mann-Whit-
ney test). Mean systolic BP for all participants was 140±16
mmHg but, when we divided them based on their view
on BP values, Subgroup 1 had lower systolic BP (136±15
mmHg) than Subgroup 2 (143±16 mmHg); t=–2.463,
P=0.015. There were significantly more patients with
systolic BP 140 mmHg in Subgroup 2 (63.6%) than in
Subgroup 1 (43.1%); Chi-square=6.396, P=0.011. Pa-
tients that didn't have appropriate view on normal BP
were taking more antihypertensive drugs (median 3, ran-
ge 1–11) than those in Subgroup 1 (median 2, range
1–5); z=–2.025, P=0.043, (Mann-Whitney test). Table 4
shows the number of used antihypertensive drugs. Ma-
jority of patients were taking more than one antihyper-
tensive drugs. Among the antihypertensive drugs used in
therapy, there were beta-blockers in 39.1%, alpha-blo-
ckers in 17.3%, RAAS inhibitors in 40.1%, vasodilators in
28.2%, diuretics in 21.3% and calcium channel blockers
in 47% of the patients. Table 5 shows the distribution of
prescribed antihypertensive drugs. 17.3% of all 202 pa-
tients started their antihypertensive treatment with delay,
even up to 40 years. In Subgroup 2, the year of AH diag-
nosis differed significantly from the year of the beginning
of the treatment than in Subgroup 1; z=–0.288, P=
0.037, Mann-Whitney test (Table 3). Most of the patients
(55%) would not take antihypertensives when BP was
lower than that preferred. Table 6 shows mean BP values
during three consecutive HD sessions. In Subgroup 2,
the patients had higher predialysis MAP (104±10 mmHg)
than in Subgroup 1 (101±9 mmHg); t=–2.362, P=0.019,
while the difference was not significant between the mid-
dle and the end-dialysis MAP. However, patients in
Subgroup 2 had intradialytic hypotension less frequently
(60.5%) than in Subgroup 1 (76.3%); Chi-square=4.289,
P=0.038. 92% of 202 patients reported symptoms during
that lower BP than the preferred (Figure 1).
DISCUSSION
The primary aim of every medical therapy is to achie-
ve beneficial outcome. Both healthcare professionals and
patients must make effort to accomplish this goal. Thera-
peutic compliance includes not only the patient’s com-
pliance with medication but also with diet, exercise, or
life style changes (28). Increasing attention is being given
to functional health literacy, which is defined as ability to
understand and act on health information (29). Even
30% of 202 interviewed patients at University Hospital
Centre Osijek we not compliant with antihypertensive
treatment. Most of the patients (55%) would not take
antihypertensives when BP was lower than that pre-
ferred. It still remains uncertain if our patients had poor-
ly regulated AH, due to insufficient compliance with
antihypertensive therapy or they were adapted to in-
creased BP. The question remains whether this was a
consequence of the frequently delayed AH treatment or
of non applicable guidelines for this particular popula-
tion of patients. A randomized controlled trial by Hayden
B. Bosworth et al. compared two groups of patients in
which the first group underwent 24-month tailored be-
havioral and educational intervention by telephone to
achieve adequate BP control, and the second group was a
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TABLE 4
Total number of used antihypertensive drugs in chronic













Groups of antihypertensive drugs in chronic hemodialy-
sed patients at the University Hospital Centre Osijek
(n=164).




Calcium channel blockers 47.0
Vasodilators 28.2
Diuretics 21.3
* Renin-angiotensin-aldosteron system blocker
Figure 1. Symptoms related to the blood pressure values lower than the declared maximum normal blood pressure.
control group with no interventions. In the six-month
preliminary outcomes, intervention group had a 9% in-
crease in a self-reported medication adherence, while the
increase in the control group was only 1% (30). Our main
objective was to determine whether a distorted view on
normal BP values had influence on patients’ compliance.
57.4% of chronic HD patients at University Hospital
Centre Osijek hold considered increased BP values for
normal, which could result in their poor BP control.
Nevertheless, the patients preferring increased BP were
older and seemed to be somehow adapted to elevated BP.
Vanessa A. Brown and colleagues found that only 30% of
patients in the general population were identified as con-
trolled and that the lack of goal complexity and self-care
may be due to the older age of participants and influences
related to generational cohort (31). Among HD patients,
limited observational data indicate that the relationships
between BP and age may differ from that of the general
population. A study by Rohrscheib et al. shows that sys-
tolic and diastolic BP is elevated in young HD patients
and declined slightly in the elderly. This could be ex-
plained by greater arterial stiffness at any age in HD pa-
tients that in the general population (32). Mean duration
of the treatment of AH in our patients was 10 years
(range 0–49). Acute illnesses are associated with higher
compliance than chronic illnesses. Long duration of treat-
ment period compromises patient’s compliance (28). 73.6%
of our 202 patients are aware that physical activity plays
an important role in regulating BP, but due to bone dis-
ease and other comorbidities they don’t have possibilities
for practising physical activity. There is inverse relation-
ship between physical activity and the occurrence of
CVD. With increased physical activity, the relative risk of
developing CVD is decreased. Even a single session of aer-
obic exercise reduced systolic, diastolic, and mean ambu-
latory blood pressure in sedentary middle-aged long-
-term-treated hypertensive patients for a substantial por-
tion of the subsequent 24 h period (33). The majority of
patients required multiple antihypertensive drugs (an-
giotensin converting enzyme inhibitors, calcium chan-
nel blockers, b-blockers, antiadrenergic drugs, vasodila-
tors, angiotensin receptors blockers), and ACE inhibitors
or ARBs are proposed as the first line of treatment in the
majority of patients. In our study, 17.7% of patients were
taking one antihypertensive drug, while the most com-
mon were two (33.5%) or three (21.3%) antihypertensive
drugs, and we even had patients (0.6%) that were taking
11 antihypertensive drugs. Most commonly prescribed
antihypertensives were calcium channel blockers (47%),
renin-angiotensin-aldosteron system inhibitors (40.%)
andb-blockers (39.1%). Diuretics were rarely prescribed,
only in those with substantial residual dieresis (3%). Pa-
tients that didn’t have appropriate view on normal BP
values had taken more antihypertensive drugs (median
3, range 1–11; P=0.043). Studies have identified several
factors affecting adherence in chronic illnesses such as
duration of the necessary treatment, regimen complexity,
side effects and dosing schedule (34). Data from different
countries show that up to 85% of patients may need mul-
tiple medications to help control their BP, and many need
three or more (35). Therapy with combinations of drugs
is more effective in achieving adequate BP control and
reducing side effects, but is associated with greater non-
compliance in some cases (36). This led to the develop-
ment of single-pill combination therapies involving al-
most all the newest classes of antihypertensive agents
(combining agents that address renin secretion and an-
other agent that is more effective in renin-independent
hypertension) (37). Most new drugs are a combination of
several drugs with better efficacy, but they are financially
inaccessible to majority of our patients. A study by E.
Poluzzi et al. has evaluated adherence to chronic cardio-
vascular drug treatments in terms of long-term persis-
tence and dose coverage. The study included the patients
already on treatment and new patients receiving their
first prescription. They were analyzed and followed for 3
years. Marked differences were seen among persistence
rates of patients already on treatment in comparison with
new patients. Actually, the patients treated with antihy-
pertensives and lipid lowering drugs showed a persis-
tence rate of 56% and 59%, respectively, in the first year,
decreasing to 42% and 52% in the second year, with no
further decrease in the third year (38).
Interdialytic ambulatory BP monitoring is a gold stan-
dard for diagnosing hypertension (39). Peridialysis BP
values are of limited accuracy in predicting interdialytic
BP, post-dialysis values are minimally better predictors
than pre-dialysis BP, and the average of pre- and post-
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TABLE 6




BP <140 mmHg (n=61)
Declared maximum normal
BP 140 mmHg (n=116)
Predialysis MAP (n, mmHg) 104±10 101±9² 104±10²
Mid dialysis MAP (n, mmHg) 99±10 98±11 99±9
End dialysis MAP (n, mmHg) 101±10 100±10 102±10
Intradialytic hypotension (n, %) 126 (67%) 45 (76.3%)³ 69 (60.5%)³
1Mean of the three mean arterial pressure (MAP) levels measured by three consecutive HD sessions.
2P= 0.019, t=–2.362; ³Chi-quare= 4.289, P= 0.038
-hemodyalisis values is marginally better than both (40).
BP obtained during dialysis should be used to ensure
hemodynamic stability and home BP monitoring for di-
agnosing and treating hypertension among HD patients
(41). The mean arterial pressure (MAP) is often used as
an expression of BP in HD patients, instead of using
solely systolic or diastolic BP. In our study, all subjects
had normal predialytic MAP below 107 mmHg (recom-
mended by the guidelines), but predialysis MAP was
higher (104±10 vs 101±9, P=0.019) in patients with in-
appropriate view on BP values. Those patients had sur-
prisingly less frequently intradialytic hypotension (60.5%
vs 76.3% in Subgroup 1), since the lower MAP is more
frequently associated with intradialytic hypotension, which
might in turn be prevented or treated with hypernatrie-
mic dialysate, frequent cessation of ultrafiltration, and
saline infusions. Patients considering elevated BP value
for normal and consequently not taking antihyperten-
sives as prescribed could have influenced the occurrence
of intradialytic hypotension. Intradialytic hypotension
not only causes discomfort, but also increases mortality.
According to recent data, a low post-dialytic BP was as-
sociated with significantly increased risk for mortality
(42). Thus, non-compliance under such circumstances
could be considered as rational, aimed to prevent even
worse complication, i.e. hypotension. Survival analysis
comparing long-term outcome in patients prone to intra-
dialytic hypotension should be conducted between those
so-called non-compliant, for not taking antihyperten-
sives regularly to avoid hypotension during dialysis, and
those strictly adherent to the medication, irrespective of
the blood pressure instability during HD session. That
would weigh the risk of the two harmful situations.
CONCLUSION
Chronic hemodialysed patients consider normal BP
values to be higher than those officially recommended.
Most of them had poorly regulated AH and did not take
antihypertensives regularly. It might be, at least in part,
due to insufficient compliance with antihypertensive ther-
apy. Except for the ignorance, the different view on nor-
mal BP and non-compliance could be contributed to the
symptoms they were experiencing when BP was below
the reported preferred values. Except from those with
distorted view on hypertension, non-compliance could
probably be expected from not a small proportion of se-
verely ill patients who were not able to make opinion on
the subject. Nevertheless, the patients preferring higher
BP were older and seemed to be somehow adapted to ele-
vated BP. The question remains whether this is a conse-
quence of frequently delayed AH treatment or non ap-
plicable guidelines for this particular population of pa-
tients.
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